Tuesday, March 15, 2011
StemCells Inc., of Palo Alto, Calif., started a Phase I/II trial of its HuCNS-SC human neural stem cells in chronic spinal cord injury in patients with both complete and incomplete degrees of paralysis who are three months to 12 months post-injury. The study will enroll 12 patients in three cohorts with thoracic spinal cord injuries who have a neurological injury level of T2-T11.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.